Sugammadex, a novel drug for neuromuscular blockade reversal;Sugammadex. Nuevo fármaco reversor del bloqueo neuromuscular

Revista Espanola de Anestesiologia y Reanimacion

Volumn 57, Issue 2, 2010, Pages 95-102

  Fernandez Mere L A ^a   Alvarez Blanco M ^b  

^a HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^b Hospital del Oriente   (Spain)

Author keywords

Antagonists; Cyclodextrins; Neuromuscular block; Postoperative residual curarization; Rocuronium; Sugammadex

Indexed keywords

ANDROSTANE DERIVATIVE; CHELATING AGENT; CHOLINERGIC RECEPTOR; GAMMA CYCLODEXTRIN DERIVATIVE; NEUROMUSCULAR BLOCKING AGENT; ROCURONIUM; SUGAMMADEX; VECURONIUM;

ANESTHETIC RECOVERY; BLOOD; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ANTAGONISM; DRUG APPROVAL; DRUG EFFECT; EUROPE; HUMAN; NEUROMUSCULAR BLOCKING; NEUROMUSCULAR SYNAPSE; POSTOPERATIVE COMPLICATION; REVIEW; SENSORY DYSFUNCTION; STATISTICS; VOMITING;

ANDROSTANOLS; ANESTHESIA RECOVERY PERIOD; CHELATING AGENTS; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; EUROPE; GAMMA-CYCLODEXTRINS; HUMANS; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR JUNCTION; NEUROMUSCULAR NONDEPOLARIZING AGENTS; POSTOPERATIVE COMPLICATIONS; RECEPTORS, CHOLINERGIC; SENSATION DISORDERS; VECURONIUM BROMIDE; VOMITING;

EID: 77952314633     PISSN: 00349356     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0034-9356(10)70171-7     Document Type: Article

References (76)

1. Naguib, M., Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 104:3 (2007), 575–581.
2. Bom, A., Clark, J.K., Palin, R., New approaches to reversal of neuromuscular block. Curr Opin Drug Discov Dev 5:5 (2002), 793–800.
3. Claudius, C., Garvey, L.H., Viby-Mogensen, J., The undesirable effects of neuromuscular blocking drugs. Anaesthesia 64:Suppl 1 (2009), 10–21.
4. Booij, L.H.D.J., van Egmond, J., Driessen, J.J., de Boer, H.D., In vivo animal studies with sugammadex. Anaesthesia 64:Suppl 1 (2009), 38–44.
5. Srivastava, A., Hunter, J.M., Reversal of neuromuscular block. Br J Anaesth 103:1 (2009), 115–129.
6. de Boer, H.D., Driessen, J.J., Marcus, M.A.E., Kerkkamp, H., Heeringa, M., Klimek, M., Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex. Anesthesiology 107:2 (2007), 239–244.
7. Fields, A.M., Vadivelu, N., Sugammadex: a novel neuromuscular blocker binding agent. Curr Opin Anaesthesiol 20:4 (2007), 307–310.
8. Plaud, B., Meretoja, O., Hofmockel, R., Raft, J., Stoddart, P., van Kuijk, J.H.M., et al. Reversal of rocuronium-induced neuromuscular blockade with sugammdex in pediatric and adult surgical patients. Anesthesiology 110:2 (2009), 284–294.
9. Yang, L.P.H., Keam, S.J., Sugammadex. A review of its use in anaesthetic practice. Drugs 69:7 (2009), 919–942.
10. Miller, R.D., Sugammadex: an opportunity to change the practice of Anesthesiology?. Anesth Analg 104:3 (2007), 477–478.
11. Martyn, J.A.J., Fagerlund, M.J., Eriksson, L.I., Basic principles of neuromuscular transmission. Anaesthesia 64:Suppl 1 (2009), 1–9.
12. Shields, M., Giovannelli, M., Mirakhur, R.K., Moppett, I., Adams, J., Hermens, Y., Org 25969 (sugammadex), a selective relaxant binding agent for antagonism of prolonged rocuronium-induced neuromuscular block. Br J Anaesth 96:1 (2006), 36–43.
13. Booij, L.H.D.J., de Boer, H.D., van Egmond, J., Reversal agents for nondepolarizing neuromuscular blockade: reasons for and development of a new concept. Semin Anesth Perioperative Med Pain 21 (2002), 92–98.
14. Nicholson, W.T., Sprung, J., Jankowski, C.J., Sugammadex: a novel agent for the reversal of neuromuscular blockade. Pharmacotherapy 27:8 (2007), 1181–1188.
15. Kilpatrick, G.J., Tilbrook, S., Drug development in anesthesia: industrial perspective. Curr Opin Anesthesiol 19:4 (2006), 385–389.
16. Della Rocca, G., Pompei, L., A novel approach to reversal of neuromuscular blockade. Minerva Anestesiol 75:5 (2009), 349–351.
17. Bom, A., Hope, F., Rutherford, S., Thompson, K., preclinical pharmacology of sugammadex. J Crit Care 24:1 (2009), 29–35.
18. Álvarez-Gómez JA, Ariño Irujo JJ, Errando Oyonarte CL, Martínez Torrente F, Roigé i Solé J, Gilsanz Rodríguez F. Empleo clínico de bloqueantes neuromusculares y su revisión. Recomendaciones del grupo de expertos de la Sociedad Española de Anestesiología, Reanimación y Tratamiento del dolor. Disponible en: http://www.sedar.es/images/stories//bnm.pdf.
19. Mirakhur, R.K., Sugammadex in clinical practice. Anaesthesia 64:Suppl 1 (2009), 45–54.
20. Gijsenbergh, F., Ramael, S., Houwing, N., van Iersel, T., First human exposure of Org 25969, a novel agent to reverse the action of rocuronium bromide. Anesthesiology 103:4 (2005), 695–703.
21. Bettelli, G., Wich muscle relaxants should be used in day surgery and when. Curr Opin Anesthesiol 19:6 (2006), 600–605.
22. Debaene, B., Plaud, B., Dilly, M.P., Donati, F., Residual paralysis in the PACU after a single intubating dose of nondepolarizing mucle relaxant with an intermediate duration of action. Anesthesiology 98:5 (2003), 1042–1048.
23. Suy, K., Morias, K., Cammu, G., Hans, P., van Duijnhoven, W.G.F., Heeringa, M., et al. Effective reversal of moderate rocuronium-or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. Anesthesiology 106:2 (2007), 283–288.
24. Epemolu, O., Bom, A., Hope, F., Mason, R., Reversal of neuromuscular blockade and simultaneous increase in plasma rocuronium concentration after the intravenous infusion of the novel reversal agent Org 25969. Anesthesiology 99:3 (2003), 632–637.
25. Arbous, M.S., Meursing, A.E.E., van Kleef, J.W., de Lange, J.J., Spoormans, H.H.A.J.M., Touw, P., et al. Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 102:2 (2005), 257–268.
26. de Boer, H.D., van Egmond, J., van de Pol, F., Bom, A., Booij, L.H.D.J., Chemical encapsulation of rocuronium by synthetic cyclodrextrin derivates: reversal of neuromuscular block in anesthetized Rhesus monkey. Br J Anaesth 96:2 (2006), 201–206.
27. Tarver, G.J., Grove, S.J.A., Buchanan, K., Bom, A., Cooke, A., Rutherford, S.J., et al. 2-O-substituted cyclodextrins as reversal agents for the neuromuscular blocker rocuronium bromide. Bioorg Med Chem 10:6 (2002), 1819–1827.
28. Pic, L.C., Novel pharmacological approaches for the antagonism of neuromuscular blockade. AANA J 73:1 (2005), 37–43.
29. Epemolu, O., Mayer, I., Hope, F., Scullion, P., Desmond, P., Liquid chromatography/ mass spectrometric bioanalysis of a modified γ-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 16:20 (2002), 1946–1952.
30. de Boer, H.D., van Egmond, J., Driessen, J.J., Booij, L.H.D., Update on the management of neuromuscular block: focus on sugammadex. Neuropsychiatr Dis Treat 3:5 (2007), 539–544.
31. Jones, R.K., Caldwell, J.E., Brull, S.J., Soto, R.G., Reversal of profound rocuronium-induced blockade with sugammadex. Anesteshiology 109:5 (2008), 816–824.
32. White, P.F., Tufanogullari, B., Sacam, O., Pavlin, E.G., Viegas, O.J., Minkowtz, H.S., et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. Anesth Analg 108:3 (2009), 846–851.
33. Veiga-Ruiz, G., Domínguez, N., Orozco, J., Janda, M., Hofmockel, R., Álvarez-Gómez, J.A., Eficacia de la reversión con sugammadex del bloqueo neuromuscular inducido por rocuronio en cirugía de larga duración. Comparación del efecto de la anestesia inhalatoria frente a intravenosa. Rev Esp Anestesiol Reanim 56:6 (2009), 349–354.
34. Khuenl-Brady, K.S., Wattwil, M., Vanacker, B.F., Lora-Tamayo, J., Rietbergen, H., Álvarez-Gómez, J.A., Suggamadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: a multicenter, randomized, controlled trial. Anesth Analg 110:1 (2009), 64–73.
35. Kopman, A.F., Sugammadex: a revolutionary approach to neuromuscular antagonism. Anesthesiology 104:4 (2006), 631–633.
36. Kopman, A.F., Eikermann, M., Antagonism of non-depolarising neuromuscular block: current practice. Anaesthesia 64:Suppl 1 (2009), 22–30.
37. Álvarez Gómez, J.A., Sugammadex, una revolución en farmacología neuromuscular. Rev Esp Anestesiol Reanim 54:4 (2007), 205–207.
38. Ortiz-Gómez, J.R., Fabregat-López, J., Sobre la extubación, la curarización residual y sus circunstancias. Rev Esp Anestesiol Reanim 55:6 (2009), 335–337.
39. Debaene, B., Plaud, B., Dilly, M.P., Donati, F., Residual paralysis in the PACU after a single intubating dose of nondepolarizing muscle relaxant with an intermediate duration of action. Anesthesiology 98:5 (2003), 1042–1048.
40. Hayes, A.H., Mirakhur, R.K., Breslin, D.S., Reid, J.E., McCourt, K.C., Postoperative residual block after intermediate-acting neuromuscular blocking drugs. Anaesthesia 56:4 (2001), 312–318.
41. Geldner, G., Sugammadex: good drugs do not replace good clinical practice. Anesth Analg 105:5 (2007), 1506–1507.
42. Fuchs-Buder, T., Claudius, C., Skovgaard, L.T., Eriksson, L.I., Mirakhur, R.K., Viby-Mogensen, J., Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: the Stockholm revision. Acta Anaesthesiol Scand 51:7 (2007), 789–808.
43. Fuchs-Buder, T., Schreiber, J-U., Meistelman, C., Monitoring neuromuscular block: an update. Anaesthesia 64:1 (2009), 82–89.
44. Naguib, M., Sugammadex may replace best clinical practice: a misconception. Anesth Analg 105:5 (2007), 1506–1507.
45. Welliver, M., New drug sugammadex: a selective relaxant binding agent. AANA J 74:5 (2006), 357–363.
46. Bom, A., Bradley, M., Cameron, K., Clark, J.K., van Egmond, J., Feilden, H., et al. A novel concept of reversing neuromuscular block: chemical encapsulation of rocuronium bromide by a cyclodextrin-based synthetic host. Angew Chem Int Ed 41:2 (2002), 275–280.
47. Szente, L., Cyclodextrins in Anesthesiology. Cyclodextrins News 20:10 (2006), 265–269.
48. De Boer, H.D., van Egmond, J., van de Pol, F., Bom, A., Booij, L.H.D.J., Sugammadex, a new reversal agent for neuromuscular block induced by rocuronium in the anesthetized Rhesus monkey. Br J Anaesth 96:4 (2006), 473–479.
49. De Boer, H.D., van Egmond, J., van de Pol, F., Bom, A., Booij, L.H.D.J., Reversal of profound rocuronium neuromuscular blockade by sugammadex in anesthetized Rhesus monkeys. Anesthesiology 104:3 (2006), 718–723.
50. Vanacker, B.F., Vermeyen, K.M., Struys, M.M.R.F., Rietbergen, H., Vandermeersch, E., Saldien, V., Reversal of rocuronium-induced neuromuscular block with the novel drug sugammadex is equally effective under maintenance anesthesia with propofol or sevoflurane. Anesth Analg 104:3 (2007), 563–568.
51. de Boer, H.D., van Egmond, J., van de Pol, F., Bom, A., Driessen, J.J., Booij, L.H.D.J., Time course of action of sugammadex (Org 25969) on rocuronium-induced block in the Rhesus monkey, using a simple model of equilibration of complex formation. Br J Anaesth 97:5 (2006), 681–686.
52. −1). Br J Anaesth 98:5 (2007), 624–627.
53. Lenz, A., Hill, G., White, P.F., Emergency use of sugammadex after failure of standar reversal drugs. Anesth Analg 104:3 (2007), 585–586.
54. Booij, L.H.D.J., Cyclodextrins and the emergence of sugammadex. Anaesthesia 64:Suppl 1 (2009), 31–37.
55. Sikharam, S., Egan, T.D., Kern, S.E., Cyclodextrins as new formulation entities and therapeutic agents. Curr Opin Anaesthesiol 18:4 (2005), 392–395.
56. Hunter, J.M., Flockton, E.A., The doughtnut and the hole: a new pharmacological concept for anaesthetists. Br J Anaesth 97:2 (2006), 123–126.
57. Zhang, M., Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal. Drugs Fut 28:4 (2003), 347–354.
58. Pühringer, F.K., Rex, C., Sielenkämper, A.W., Claudius, C., Larsen, P.B., Prins, M.E., et al. Reversal of profound high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different points. Anesthesiology 109:2 (2008), 188–197.
59. Adam, J.M., Bennet, D.J., Bom, A., Clark, J.K., Feilden, H., Hutchinson, E.J., et al. Cyclorextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 45:9 (2002), 1806–1816.
60. Zhang, M., Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal. Drugs Fut 28:4 (2003), 347–354.
61. Sparr, H.J., Vermeyer, K.M., Beaufort, A.M., Rietbergen, H., Proost, J.H., Saldien, V., et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study. Anesthesiology 106:5 (2007), 935–943.
62. McIntyre, J.A., Castañer, J., Sugammadex sodium. Agent for reversal of neuromuscular blockade. Drugs Fut 30:8 (2005), 780–784.
63. Groudine, S.B., Soto, R., Lien, C., Drover, D., Roberts, K., A randomized, dose-finding, phase II study of the selective relaxant binding drug, sugammadex, capable of safely reversing profound rocuronium-induced neuromuscular block. Anesth Analg 104:3 (2007), 555–562.
64. Fields, A.M., Vadivelu, N., Sugammadex: a novel neuromuscular blocker binding agent. Curr Opin Anaesthesiol 20:4 (2007), 307–310.
65. Sacan, O., White, P.F., Tufanogullari, B., Klein, K., Sugammadex reversal of rocuronium-induced neuromuscular blockade: a comparison with neostigmine-glycopirrolate and edrophonium-atropine. Anesth Analg 104:3 (2007), 569–574.
66. Craig, R.G., Hunter, J.M., Neuromuscular blocking drugs and their antagonists in patients with organ disease. Anaesthesia 64:Suppl 1 (2009), 55–65.
67. Lee, C., Jahr, J.S., Candiotti, K.A., Warriner, B., Zornov, M.H., Naguib, M., Reversal of profound neuromuscular block by sugammdex administered three minutes after rocuronium. A comparison with spontaneus recovery from succinylcholine. Anesthesiology 110:5 (2009), 1020–1025.
68. Eleveld, D.J., Kuizenga, K., Proost, J.H., Wierda, J.M.K.H., A temporary decrease in twitch response during reversal of rocuronium-induced muscle relaxation with a small dose of sugammadex. Anesth Analg 104:3 (2007), 582–584.
69. Dahl, V., Pendeville, P.E., Hollmann, M.W., Heier, T., Abels, E.A.M., Blobner, M., Safety and efficacy of sugammadex fro the reversal of rocuroniuminduced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. Eur J Anaesthesiol 26:10 (2009), 874–884.
70. Miller, R.D., Sugammadex: an opportunity to change the practice of Anesthesiology?. Anesth Analg 104:3 (2007), 477–478.
71. Cammu, G., De Kam, P.J., Demeyer, I., Decoopman, M., Peeters, P.A., Smeets, J.M., et al. Safety and tolerability of single intravenous doses of sugammadex administered simultaneously with rocuronium or vecuronium in healthy volunteers. Br J Anaesth 100:3 (2008), 373–379.
72. Caldwell, J.E., Miller, R.D., Clinical implications of sugammadex. Anaesthesia 64:suppl 1 (2009), 66–72.
73. Weaver, J.M., New drugs on the horizon may improve the quality and safety of anesthesia. Anesth Prog 55:2 (2008), 27–28.
74. Flockton, E.A., Mastronardi, P., Hunter, J.M., Comar, C., Mirakhur, R.K., Aguilera, L., et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. Br J Anaesth 100:5 (2008), 622–630.
75. Lee, C., Goodbye suxamethonium!. Anaesthesia 64:Suppl 1 (2009), 73–81.
76. de Boer, H.D., Driessen, J.J., van Egmond, J., Booij, L.H.D.J., Non-steroidal neuromuscular blocking agents to re-establish paralysis after reversal of rocuronium-induced neuromuscular block with sugammadex. Can J Anesth 55:2 (2008), 124–125.